A short-term diagnostic and economic impact model of neonatal screening for cystic fibrosis;Modellierung der kurzfristigen diagnostischen und ökonomischen Auswirkungen eines Neugeborenen-screenings auf Mukoviszidose

Klinische Padiatrie

Volumn 223, Issue 2, 2011, Pages 96-103

  Rasch, A ^a   Perleth, M ^a  

^a Gemeinsamer Bundesausschuss   (Germany)

Author keywords

cystic fibrosis; decision modeling; economics; model; neonatal screening

Indexed keywords

ARTICLE; CONTROLLED STUDY; CYSTIC FIBROSIS; DIAGNOSTIC VALUE; DNA DETERMINATION; GERMANY; HEALTH CARE COST; HUMAN; INTERMETHOD COMPARISON; NEWBORN SCREENING; SENSITIVITY AND SPECIFICITY;

COHORT STUDIES; CYSTIC FIBROSIS; DECISION SUPPORT TECHNIQUES; GERMANY; HEALTH CARE COSTS; HEALTH PLAN IMPLEMENTATION; HUMANS; INFANT, NEWBORN; MODELS, ECONOMIC; NATIONAL HEALTH PROGRAMS; NEONATAL SCREENING; PREDICTIVE VALUE OF TESTS;

EID: 79953061760     PISSN: 03008630     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0031-1271667     Document Type: Article

References (22)

1. Cystic Fibrosis Mutation Database. http://www.genet.sickkids.on.ca/cftr/ Home.html 2010
2. Beker LT, Russek-Cohen E, Fink RJ. Stature as a prognostic factor in cystic fibrosis survival. J Am Diet Assoc 2001 101 438-442 (Pubitemid 33712127)
3. Castellani C, Picci L, Scarpa M et al,. Cystic fibrosis carriers have higher neonatal immunoreactive trypsinogen values than non-carriers. Am J Med Genet A 2005 135 142-144 (Pubitemid 40769963)
4. Comeau AM, Parad RB, Dorkin HL et al,. Population-based newborn screening for genetic disorders when multiple mutation DNA testing is incorporated: a cystic fibrosis newborn screening model demonstrating increased sensitivity but more carrier detections. Pediatrics 2004 113 1573-1581 (Pubitemid 38697961)
5. Corey M, Farewell V. Determinants of mortality from cystic fibrosis in Canada, 1970-1989. Am J Epidemiol 1996 143 1007-1017 (Pubitemid 26140328)
6. Emerson J, Rosenfeld M, McNamara S et al,. Pseudomonas aeruginosa and other predictors of mortality and morbidity in young children with cystic fibrosis. Pediatr Pulmonol 2002 34 91-100 (Pubitemid 34809519)
7. Farrell PM, Lai HJ, Li Z et al,. Evidence on improved outcomes with early diagnosis of cystic fibrosis through neonatal screening: enough is enough! J pediatr 2005 147 3 Suppl S30-S36 (Pubitemid 41400256)
8. Heimeshoff M, Schreyögg J, Tiemann O et al,. Cost of illness of cystic fibrosis. 2. Jahreskonferenz der Deutschen Gesellschaft für Gesundheitsökonomie (dggö), Abstract Band. 2010
9. Klinikum der Universität München. Stellungnahme zum Thema Screening auf Cystische Fibrose (Mukoviszidose) (persönliche Kommunikation). 2008
10. Konstan MW, Butler SM, Wohl ME et al,. Growth and nutritional indexes in early life predict pulmonary function in cystic fibrosis. J Pediatr 2003 142 624-630 (Pubitemid 36737164)
11. Medizinische Hochschule Hannover IfHZPFuG. Stellungnahme zum Thema Screening auf Cystische Fibrose (Mukoviszidose) (persönliche Kommunikation). 2008
12. Pollitt RJ, Dalton A, Evans S et al,. Neonatal screening for cystic fibrosis in the Trent region (UK): two-stage immunoreactive trypsin screening compared with a three-stage protocol with DNA analysis as an intermediate step. J Med Screen 1997 4 23-28
13. Ranieri E, Lewis BD, Gerace RL et al,. Neonatal screening for cystic fibrosis using immunoreactive trypsinogen and direct gene analysis: four years' experience. BMJ 1994 308 1469-1472
14. Sarles J, Berthezene P, Le Louarn C et al,. Combining immunoreactive trypsinogen and pancreatitis-associated protein assays, a method of newborn screening for cystic fibrosis that avoids DNA analysis. J Pediatr 2005 147 302-305 (Pubitemid 41345757)
15. Sharma R, Florea VG, Bolger AP et al,. Wasting as an independent predictor of mortality in patients with cystic fibrosis. Thorax 2001 56 746-750 (Pubitemid 32917542)
16. Simpson N, Anderson R, Sassi F et al,. The cost-effectiveness of neonatal screening for cystic fibrosis: an analysis of alternative scenarios using a decision model. Cost Effectiveness and Resource Allocation 2005 3 8
17. Sims EJ, Mugford M, Clark A et al,. Economic implications of newborn screening for cystic fibrosis: a cost of illness retrospective cohort study. Lancet 2007 369 1187-1195 (Pubitemid 46546435)
18. Statistisches Bundesamt. Lebendgeborene 2008 nach der Staatsangehörigkeit und dem Geschlecht des Kindes sowie nach der Staatsangehörigkeit der Eltern. 2009
19. Stern M, Sens S, Wiedemann B et al,. Qualitätssicherung Mukoviszidose. Überblicküber den Gesundheitszustand der Patienten in Deutschland 2008. Bad Honnef Hippocampus Verlag 2009
20. van den Akker-van Marle ME, Dankert HM, Verkerk PH et al,. Cost-effectiveness of 4 neonatal screening strategies for cystic fibrosis. Pediatrics 2006 118 896-905 (Pubitemid 46090029)
21. World Health Organisation (WHO). The molecular genetic epidemiology of cystic fibrosis. http://www.who.int/genomics/publications/en/HGN-WB-04 02-report.pdf 2010
22. Wunderlich P, Stopsack M, Paul KD et al,. Mukoviszidose-Screening bei Neugeborenen im Regierungsbezirk Dresden. Ergebnisse vom 1.6.1996 bis zum 31.3.2000. [Mucoviscidosis screening of newborn infants in the Dresden district. Results from 1 June 1996 to 31 March 2000]. Dtsch Med Wochenschr 2000 125 1356-1360